Toon Van Gorp - Dissemin

Papers authored by Toon Van Gorp

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2022 T. Van Gorp

Conversations and controversies in first-line maintenance therapy for advanced ovarian cancer

Upload

T. Van Gorp

New HRD tests on the horizon

Upload

T. Van Gorp

Discussant Best oral session

Upload

T. Van Gorp

The role of IO in in first-line endometrial cancer

Upload

Roman Kocian, Christhardt Koehler, Sylva Bajsova, Klara Benesova, Ignacio Zapardiel, Giampaolo Di Martino, Luc van Lonkhuijzen, Borek Sehnal, Octavio Arencibia Sanchez, Blanca Gil Ibanez, Fabio Martinelli, Jiri Presl, Lubos Minar, Radim Marek, Peter Kascak and 5 other authors

2022-RA-959-ESGO Pelvic sentinel lymph nodedistribution; the final outcome of the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)

Upload

Liselore Loverix, Ignace Vergote, Adriaan Vanderstichele, Pieter Busschaert, Bram Boeckx, Tom Venken, Els van Nieuwenhuysen, Thaïs Baert, Sileny Han, Patrick Neven, Patrick Berteloot, Siel Olbrecht, Tina Laga, Diether Lambrechts, Toon van Gorp

2022-RA-1473-ESGO Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in recurrent ovarian cancer – results of the Leuven HRD test

Upload

Tina Laga, Pieter Busschaert, Siel Olbrecht, Liselore Loverix, Francesca Lodi, Thaïs Baert, Toon Van Gorp

, Anne-Sophie Van Rompuy, Ignace Vergote, Diether Lambrechts, Els Van Nieuwenhuysen

2022-RA-1136-ESGO A single-cell map of rare ovarian cancer

Upload

Sander Dumont, Vincent Vandecaveye, Raphaëla Carmen Dresen, Els van Nieuwenhuysen, Thaïs Baert, Sileny Han, Patrick Neven, Patrick Berteloot, Frédéric Amant, Toon van Gorp

2022-RA-884-ESGO Whole-body diffusion-weighted MRI (WB-DWI/MRI) for the prediction of resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer

Upload

Liselore Loverix, Rawand Salihi, Anne-Sophie van Rompuy, Adriaan Vanderstichele, Els van Nieuwenhuysen, Thaïs Baert, Philip Debruyne, Nathalie Cornez, Stéphanie Henry, Patrick Neven, Sileny Han, Patrick Berteloot, Siel Olbrecht, Tina Laga, Pieter Busschaert and 2 other authors

2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer

Upload

Roman Kocian, Christhardt Koehler, Sylva Bajsova, Jiri Jarkovsky, Ignacio Zapardiel, Giampaolo Di Martino, Luc van Lonkhuijzen, Borek Sehnal, Octavio Arencibia Sanchez, Blanca Gil Ibanez, Fabio Martinelli, Jiri Presl, Lubos Minar, Radim Marek, Peter Kascak and 5 other authors

2022-RA-908-ESGO The importance of pathological ultrastaging for sentinel lymph nodebiopsy in cervical cancer, the final outcome of the Sentix study (CEEGOG-CX01; ENGOT-CX2; NCT02494063)

Upload

T. Van Gorp

Immunotherapy in ovarian cancer: Current Evidence and Future Prospects

Upload

T. Van Gorp

Overview of Systemic Treatment for Recurrent Ovarian Cancer

Upload

This paper was not found in any repository, but could be made available legally by the author.

K. N. Moore, D. Lorusso, A. Oaknin, S. Pignata, H. Denys, N. Colombo, T. Van Gorp

, J. Konner, M. Romeo Marin, P. Harter, C. Murphy, Y. Tu, F. Zhu, B. Esteves, M. Method and 4 other authors

605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

Upload

N. Colombo, T. Van Gorp

, U. A. Matulonis, A. Oaknin, R. N. Grisham, G. Fleming, A. Olawaiye, I. C. Tudor, H. I. Pashova, D. Lorusso

536P Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study

Upload

U. A. Matulonis, K. N. Moore, D. Lorusso, A. Oaknin, S. Pignata, H. Denys, N. Colombo, T. Van Gorp

, J. Konner, M. Romeo Marin, P. Harter, C. Murphy, Y. Tu, F. Zhu, B. Esteves and 4 other authors

592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

Upload

N. Colombo, T. Van Gorp

, U. A. Matulonis, A. Oaknin, R. N. Grisham, G. F. Fleming, A. B. Olawaiye, I. C. Tudor, H. I. Pashova, D. Lorusso, D. Nguyen

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study

Upload

D. Cibula, C. Köhler, S. Bajsová, S. Sebestova, I. Zapardiel, G. Di Martino, L. R. van Lonkhuijzen, B. Sehnal, O. Arencibia Sánchez, B. Gil Ibañez, F. Martinelli, J. Presl, L. Minář, R. Marek, P. Kascak and 5 other authors

526MO Pathological assessment of sentinel lymph node in early-stage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)

Upload

K. Moore, D. Lorusso, A. Oaknin, S. Pignata, H. Denys, N. Colombo, T. Van Gorp

, J. Konner, M. Romeo, P. Harter, C. Murphy, D. O'Malley, Y. Tu, F. Zhu, B. Esteves and 4 other authors

Population Pharmacokinetic (PK) Analysis of Mirvetuximab Soravtansine (MIRV) in Patients With Folate Receptor α (FRα)-Positive Cancer

Upload

U. A. Matulonis, K. Moore, D. Lorusso, A. Oaknin, S. Pignata, H. Denys, N. Colombo, T. Van Gorp

, J. Konner, M. Romeo, P. Harter, C. Murphy, D. O'Malley, T. Yu, B. Esteves and 3 other authors

Exposure Response (ER) Analysis of Mirvetuximab Soravtansine (MIRV) in Patients With Folate Receptor α (FRα)-Positive Cancer

Upload

Ursula Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp

, Jason Konner, Margarita Romeo Marin, Philipp Harter, Conleth Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method and 1 other authors

Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4)

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

Papers authored by Toon Van Gorp